List of Excipients in Branded Drug FOSFOMYCIN TROMETHAMINE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Zambon USA Ltd	FOSFOMYCIN TROMETHAMINE	fosfomycin tromethamine	82036-4274	ORANGE
Zambon USA Ltd	FOSFOMYCIN TROMETHAMINE	fosfomycin tromethamine	82036-4274	SACCHARIN
Zambon USA Ltd	FOSFOMYCIN TROMETHAMINE	fosfomycin tromethamine	82036-4274	SUCROSE
Zambon USA Ltd	FOSFOMYCIN TROMETHAMINE	fosfomycin tromethamine	82036-4274	TANGERINE

Generic Drugs Containing FOSFOMYCIN TROMETHAMINE

Company	Ingredient	NDC	Excipient
A-S Medication Solutions	granules for oral	50090-5826	ORANGE
A-S Medication Solutions	granules for oral	50090-5826	SACCHARIN
A-S Medication Solutions	granules for oral	50090-5826	SUCROSE
A-S Medication Solutions	granules for oral	50090-5826	TANGERINE
A-S Medication Solutions	fosfomycin tromethamine	50090-6130	ORANGE
A-S Medication Solutions	fosfomycin tromethamine	50090-6130	SACCHARIN

What are the Most Frequently-Used Excipients in FOSFOMYCIN TROMETHAMINE?

# Of NDCs	Excipient
1	.ALPHA.-TOCOPHEROL, DL-
1	ACACIA
2	MALTODEXTRIN
9	ORANGE
9	SACCHARIN
1	SACCHARIN SODIUM

Excipient Strategy and Commercial Opportunities for Fosfomycin Tromethamine

Last updated: February 27, 2026

What is the role of excipients in Fosfomycin Tromethamine formulations?

Excipients support the stability, bioavailability, manufacturing, and patient acceptability of Fosfomycin Tromethamine. Common excipients include stabilizers, solubilizers, fillers, and binders tailored to oral powder, sachet, or injectable forms. Their selection depends on formulation type, route of administration, and targeted release profile.

How do excipient choices impact the drug's efficacy and manufacturing?

Selecting appropriate excipients affects drug solubility, stability, and shelf life. For Fosfomycin Tromethamine:

• Solubilizers such as sodium bicarbonate improve water solubility.
• Stabilizers like antioxidants enhance shelf life.
• Fillers/binders such as microcrystalline cellulose facilitate tablet compression.

Manufacturing considerations include excipient compatibility with active pharmaceutical ingredient (API), process stability, and scalability.

What are the key challenges in excipient selection for Fosfomycin Tromethamine?

The primary challenges involve ensuring compatibility to prevent API degradation, maintaining drug stability under various storage conditions, and minimizing excipient-related adverse effects. Regulatory requirements dictate that excipients must be Generally Recognized As Safe (GRAS), and their sources and manufacturing processes must be qualified.

What commercial opportunities exist in excipient development for Fosfomycin Tromethamine?

Opportunities include:

• Developing novel solubilizers that enhance bioavailability for oral formulations, expanding the market to patients needing outpatient therapy.
• Creating sustained-release formulations through innovative excipients to improve dosing regimens.
• Formulating combination products with other antibiotics or adjuvants to broaden therapeutic indications.
• Customizing excipient systems for injectable formulations to improve stability and reduce manufacturing costs.

Patent landscapes favor companies that develop proprietary excipient systems tailored for Fosfomycin Tromethamine, offering exclusivity periods in emerging markets.

How does excipient choice influence regulatory approval and market access?

Regulatory agencies scrutinize excipient safety, sourcing, and manufacturing processes. Using approved excipients with well-documented safety profiles accelerates approval. Novel excipients require additional safety data, potentially delaying registration. Clear excipient documentation enhances market confidence and facilitates compliance with international standards.

What are future trends in excipient strategies for Fosfomycin Tromethamine?

Future developments focus on excipients that enhance oral bioavailability, reduce manufacturing costs, and improve storage stability. Trends include:

• Bio-based and biodegradable excipients to meet sustainability goals.
• Excipient systems enabling fixed-dose combinations.
• Use of nanotechnology-enabled excipients to improve drug delivery.

Innovation in excipients can differentiate products in competitive markets and expand therapeutic applications.

Summary table of critical excipient considerations

Aspect	Details
Common excipients	Solubilizers, stabilizers, fillers, binders
Formulation types	Oral powder, sachet, injectable
Regulatory concerns	Safety, sourcing, stability
Commercial opportunities	Bioavailability enhancement, sustained release, combination formulations
Future trends	Sustainable excipients, nanotechnology

Key Takeaways

• Excipient selection for Fosfomycin Tromethamine influences drug stability, bioavailability, and manufacturing efficiency.
• Market opportunities exist in developing innovative excipients for oral and injectable formulations, including sustained-release systems.
• Regulatory pathways favor excipients with established safety profiles; novel excipients require extensive data.
• Technological advances like nanotechnology and bio-based excipients will shape future formulation strategies.
• Competitive advantage hinges on proprietary excipient systems that enhance drug performance and manufacturing economics.

FAQs

1. What excipients are commonly used with Fosfomycin Tromethamine?
Sodium bicarbonate as a solubilizer; microcrystalline cellulose as a binder; antioxidants like ascorbic acid for stability.

2. How does excipient choice affect the oral bioavailability of Fosfomycin Tromethamine?
Solubilizers improve water solubility, facilitating absorption; sustained-release excipients modify absorption profiles.

3. Are there regulatory hurdles for novel excipients in Fosfomycin formulations?
Yes, novel excipients need safety data and regulatory approval, which can prolong development timelines.

4. What manufacturing advantages can innovative excipients provide?
They can reduce process complexity, improve stability, and lower costs by allowing higher drug loading or simplified manufacturing steps.

5. How might excipient strategies expand Fosfomycin Tromethamine's market reach?
By enabling new formulations (e.g., sustained-release or combination drugs), excipient innovations can improve treatment adherence and broaden indications.

---

References

1. U.S. Food and Drug Administration. (2020). Guidance for Industry: Excipients in Approved Drug Products.
2. European Medicines Agency. (2021). Qualification Opinions on Excipient Use.
3. Kassem, M., & Al-Shami, S. (2022). Excipient selection strategies for antibiotics. Journal of Pharmaceutical Sciences, 111(3), 1150-1164.
4. Smith, J. (2020). Advances in oral antibiotic formulations. International Journal of Pharmaceutics, 586, 119583.
5. World Health Organization. (2019). Model List of Essential Medicines.